Trial site
Northwest Clinical Trials
- 6running trials
- 5closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Conditions
- Alzheimer disease4 trials
- Migraine3 trials
- Depression1 trial
- Type 2 diabetes1 trial
- Phase
- Phase 39 trials
- Phase 22 trials
- Status
- Active, not recruiting5 trials
- Completed4 trials
- Recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Eli Lilly and Company7 trials
- Biohaven Pharmaceuticals, Inc.2 trials
- Otsuka Pharmaceutical Development & Commercialization, Inc.1 trial
- TriGemX Bio, Inc.1 trial
Running trials
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Active, not recruiting
Active, not recruiting
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Active, not recruiting
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Alzheimer disease1 recruiting
Closed trials
Completed
Completed
Completed
Terminated
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
Completed
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Site data: ClinicalTrials.govUpdated 15 Nov 2026